Segment & Geographic Data
Quant-Grade Normalized (live API)
API & CSV Delivery
Context Therapeutics Inc's Business Segments
Context Therapeutics Inc's reported revenue by business segment and by geographic region, quarterly and annual, normalized against the consolidated income statement. Free below: the top 3 rows per table, this quarter and this fiscal year. Subscriber access adds the full segment history and operating income by segment.
Segment Data As of FY
Reportable Segments
1
Largest Segment
Reportable
Total Revenue
-
Regions Reported
-
Revenue Share by Reportable Segment - FY
- Reportable0%
Revenue by Reportable Segment - FY
| Segment | Revenue (Millions) | % of Total |
|---|---|---|
| Reportable | - | - |
Annual Results
Revenue Share by Reportable Segment - FY
- Reportable0%
Revenue by Reportable Segment - FY
| Segment | Revenue (Millions) | % of Total |
|---|---|---|
| Reportable | - | - |
Description of Context Therapeutics Inc
Context Therapeutics Inc is a biotechnology company focused on the development of novel therapies for hormone-driven cancers. The company was founded in 2016 and is headquartered in Philadelphia, Pennsylvania.
The primary mission of Context Therapeutics is to discover and develop innovative treatments that target the genomic drivers of hormone receptor-positive (HR+) cancers, including breast, ovarian, and endometrial cancers. HR+ cancers are characterized by the presence of hormone receptors on the surface of cancer cells that promote their growth and proliferation. By targeting specific genetic and molecular pathways involved in HR+ cancers, Context Therapeutics aims to develop therapies that provide better outcomes for patients with these types of cancers.
The company utilizes a proprietary platform known as the HR+ Liquid Assay System (HR+LAS) to identify and validate potential drug targets for HR+ cancers. This platform combines advanced genomics and transcriptomics technologies to precisely measure gene expression changes in HR+ cancers. By identifying unique gene signatures associated with HR+ cancers, Context Therapeutics can develop therapies that specifically target these abnormal gene pathways.
One of the key therapeutic candidates being developed by Context Therapeutics is Apristor (onapristone extended-release), which is a selective progesterone receptor antagonist. Progesterone receptors play a crucial role in the growth and progression of HR+ cancers, and Apristor is designed to inhibit the activity of these receptors. In preclinical studies, Apristor has shown promising results in inhibiting the growth of HR+ cancer cells and sensitizing them to other anti-cancer treatments, such as chemotherapy and targeted therapies.
In addition to Apristor, Context Therapeutics has a pipeline of other potential drug candidates in various stages of development. These candidates include next-generation progesterone receptor antagonists, as well as combination therapies that target multiple molecular pathways involved in HR+ cancers.
To further support its drug development efforts, Context Therapeutics actively collaborates with leading academic institutions, research organizations, and clinical centers. These collaborations allow the company to access the latest scientific advancements and leverage expertise in the field of hormone-driven cancers.
Overall, Context Therapeutics Inc is dedicated to advancing precision medicine for HR+ cancers by developing targeted therapies that address the underlying genetic drivers of these diseases. Through its innovative approach and collaborative partnerships, the company strives to improve patient outcomes and ultimately transform the standard of care for HR+ cancer patients.
The primary mission of Context Therapeutics is to discover and develop innovative treatments that target the genomic drivers of hormone receptor-positive (HR+) cancers, including breast, ovarian, and endometrial cancers. HR+ cancers are characterized by the presence of hormone receptors on the surface of cancer cells that promote their growth and proliferation. By targeting specific genetic and molecular pathways involved in HR+ cancers, Context Therapeutics aims to develop therapies that provide better outcomes for patients with these types of cancers.
The company utilizes a proprietary platform known as the HR+ Liquid Assay System (HR+LAS) to identify and validate potential drug targets for HR+ cancers. This platform combines advanced genomics and transcriptomics technologies to precisely measure gene expression changes in HR+ cancers. By identifying unique gene signatures associated with HR+ cancers, Context Therapeutics can develop therapies that specifically target these abnormal gene pathways.
One of the key therapeutic candidates being developed by Context Therapeutics is Apristor (onapristone extended-release), which is a selective progesterone receptor antagonist. Progesterone receptors play a crucial role in the growth and progression of HR+ cancers, and Apristor is designed to inhibit the activity of these receptors. In preclinical studies, Apristor has shown promising results in inhibiting the growth of HR+ cancer cells and sensitizing them to other anti-cancer treatments, such as chemotherapy and targeted therapies.
In addition to Apristor, Context Therapeutics has a pipeline of other potential drug candidates in various stages of development. These candidates include next-generation progesterone receptor antagonists, as well as combination therapies that target multiple molecular pathways involved in HR+ cancers.
To further support its drug development efforts, Context Therapeutics actively collaborates with leading academic institutions, research organizations, and clinical centers. These collaborations allow the company to access the latest scientific advancements and leverage expertise in the field of hormone-driven cancers.
Overall, Context Therapeutics Inc is dedicated to advancing precision medicine for HR+ cancers by developing targeted therapies that address the underlying genetic drivers of these diseases. Through its innovative approach and collaborative partnerships, the company strives to improve patient outcomes and ultimately transform the standard of care for HR+ cancer patients.
Context Therapeutics Inc. is a clinical-stage biopharmaceutical company primarily focused on the development of innovative cancer therapies. The company has a unique approach that centers around targeting womens cancers and harnessing advances in molecular biology, immunotherapy, and hormone receptor biology. Below, I will provide a detailed description of the different segments, products, and services that Context Therapeutics Inc. may offer.
Segments:
1. Clinical Development:
- Context Therapeutics focuses on developing its product candidates through rigorous clinical trials, with an emphasis on safety and efficacy.
- The company engages in preclinical and clinical research, collaborating with leading research institutions and clinical networks to advance its pipeline.
2. R&D (Research and Development):
- The R&D segment is pivotal for discovering and developing new therapeutic agents aimed at treating various forms of cancer, particularly those affecting women.
- The company invests significantly in understanding the underlying biology of tumors and patient-specific factors that influence treatment outcomes.
3. Regulatory Affairs:
- This segment involves navigating the regulatory landscape to ensure compliance with health authorities, particularly the FDA.
- Context Therapeutics aims to establish a streamlined pathway for its product candidates, adhering to good manufacturing practices (GMP) and ensuring that all clinical trial protocols meet regulatory expectations.
4. Partnership and Collaborations:
- Context Therapeutics actively seeks partnerships with academic institutions, research organizations, and pharmaceutical companies to enhance its development capabilities and share resources.
- Collaborative efforts may include co-developing therapies, sharing data, and accessing broader patient populations for clinical studies.
Products:
1. Lead Product Candidates:
- Onapristone (BRCA1/2-deficient tumors): This is an investigational oral medication designed to target progesterone receptors, particularly in breast and endometrial cancers. Onapristone aims to slow tumor growth by inhibiting the action of progesterone, which is often involved in hormone-driven malignancies.
- Context’s Immunotherapy Approaches: The company is exploring various combination strategies utilizing immune-oncology approaches to enhance patient responses to treatment, possibly including checkpoint inhibitors and other immunomodulatory therapies.
2. Pipeline Development:
- Context Therapeutics is expected to expand its pipeline with additional compounds in various stages of research. These products may cover a range of solid tumors with a focus on female-specific cancers such as breast and ovarian cancer.
3. Preclinical Programs:
- In addition to its clinical-stage products, Context is likely working on earlier-stage preclinical candidates that have potential in oncology.
- These products are concentrated on novel mechanisms of action that may provide future treatment options for patients resistant to current therapies.
Services:
1. Clinical Research Services:
- Context Therapeutics may offer services related to clinical trial design, management, and execution. This includes patient recruitment, data collection, monitoring compliance, and analyzing trial results.
- The company may also engage in post-marketing surveillance and real-world evidence generation to evaluate the long-term effectiveness and safety of its products.
2. Consultative Services:
- Leveraging its expertise in drug development, the company might provide consultative services to other organizations looking to navigate the complexities of oncology drug development.
- These services may include strategic planning around drug development, regulatory submissions, and market access strategies.
3. Educational Programs:
- Context Therapeutics may engage in educational initiatives aimed at healthcare professionals and stakeholders regarding advancements in the field of womens oncology.
- These programs are designed to disseminate crucial information about emerging therapies and their clinical applications.
4. Advocacy and Patient Support:
- The company could also engage in activities focused on patient advocacy, aiming to inform and empower those affected by womens cancers.
- This might include partnerships with patient organizations, public awareness campaigns, and resources designed to help patients navigate their treatment journeys.
In summary, Context Therapeutics Inc. appears to be working diligently across multiple segments in the oncology landscape, with a strong focus on developing therapies for womens cancers. Their product pipeline and clinical research efforts underscore a commitment to advancing innovative treatment options, while their consultative and educational services demonstrate engagement with the broader medical community.
Segments:
1. Clinical Development:
- Context Therapeutics focuses on developing its product candidates through rigorous clinical trials, with an emphasis on safety and efficacy.
- The company engages in preclinical and clinical research, collaborating with leading research institutions and clinical networks to advance its pipeline.
2. R&D (Research and Development):
- The R&D segment is pivotal for discovering and developing new therapeutic agents aimed at treating various forms of cancer, particularly those affecting women.
- The company invests significantly in understanding the underlying biology of tumors and patient-specific factors that influence treatment outcomes.
3. Regulatory Affairs:
- This segment involves navigating the regulatory landscape to ensure compliance with health authorities, particularly the FDA.
- Context Therapeutics aims to establish a streamlined pathway for its product candidates, adhering to good manufacturing practices (GMP) and ensuring that all clinical trial protocols meet regulatory expectations.
4. Partnership and Collaborations:
- Context Therapeutics actively seeks partnerships with academic institutions, research organizations, and pharmaceutical companies to enhance its development capabilities and share resources.
- Collaborative efforts may include co-developing therapies, sharing data, and accessing broader patient populations for clinical studies.
Products:
1. Lead Product Candidates:
- Onapristone (BRCA1/2-deficient tumors): This is an investigational oral medication designed to target progesterone receptors, particularly in breast and endometrial cancers. Onapristone aims to slow tumor growth by inhibiting the action of progesterone, which is often involved in hormone-driven malignancies.
- Context’s Immunotherapy Approaches: The company is exploring various combination strategies utilizing immune-oncology approaches to enhance patient responses to treatment, possibly including checkpoint inhibitors and other immunomodulatory therapies.
2. Pipeline Development:
- Context Therapeutics is expected to expand its pipeline with additional compounds in various stages of research. These products may cover a range of solid tumors with a focus on female-specific cancers such as breast and ovarian cancer.
3. Preclinical Programs:
- In addition to its clinical-stage products, Context is likely working on earlier-stage preclinical candidates that have potential in oncology.
- These products are concentrated on novel mechanisms of action that may provide future treatment options for patients resistant to current therapies.
Services:
1. Clinical Research Services:
- Context Therapeutics may offer services related to clinical trial design, management, and execution. This includes patient recruitment, data collection, monitoring compliance, and analyzing trial results.
- The company may also engage in post-marketing surveillance and real-world evidence generation to evaluate the long-term effectiveness and safety of its products.
2. Consultative Services:
- Leveraging its expertise in drug development, the company might provide consultative services to other organizations looking to navigate the complexities of oncology drug development.
- These services may include strategic planning around drug development, regulatory submissions, and market access strategies.
3. Educational Programs:
- Context Therapeutics may engage in educational initiatives aimed at healthcare professionals and stakeholders regarding advancements in the field of womens oncology.
- These programs are designed to disseminate crucial information about emerging therapies and their clinical applications.
4. Advocacy and Patient Support:
- The company could also engage in activities focused on patient advocacy, aiming to inform and empower those affected by womens cancers.
- This might include partnerships with patient organizations, public awareness campaigns, and resources designed to help patients navigate their treatment journeys.
In summary, Context Therapeutics Inc. appears to be working diligently across multiple segments in the oncology landscape, with a strong focus on developing therapies for womens cancers. Their product pipeline and clinical research efforts underscore a commitment to advancing innovative treatment options, while their consultative and educational services demonstrate engagement with the broader medical community.